Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SBLOF'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.22 Med: 29.73 Max: 442.68
Current: 18.11
During the past years, Shin Nippon Biomedical Laboratories's highest Shiller PE Ratio was 442.68. The lowest was 13.22. And the median was 29.73.
SBLOF's Shiller PE Ratio is ranked better than 66.23% of 77
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.23
vs SBLOF: 18.11
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Shin Nippon Biomedical Laboratories's adjusted earnings per share data for the three months ended in Mar. 2026 was $0.348. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.53 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Shin Nippon Biomedical Laboratories (OTCPK:SBLOF) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Shin Nippon Biomedical Laboratories Shiller PE Ratio Related Terms
Shin Nippon Biomedical Laboratories Shiller PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories Shiller PE Ratio Chart
SBLOF vs TMO, DHR, IDXX: Shiller PE Ratio Comparison
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories Shiller PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's Shiller PE Ratio falls into.
Shin Nippon Biomedical Laboratories Shiller PE Ratio Calculation
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Shin Nippon Biomedical Laboratories (SBLOF) has a Shiller PE Ratio of 17.28 as of Aug. 20, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Shin Nippon Biomedical Laboratories and its competitors. This is 42% below median its historical median of 29.73. Over the past decade, Shin Nippon Biomedical Laboratories' Shiller PE Ratio has ranged from 13.22 to 442.68. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #26 out of 77 companies in the Medical Diagnostics & Research industry, placing it in the top 33.8%.
Is Shin Nippon Biomedical Laboratories' Shiller PE Ratio too high?
Shin Nippon Biomedical Laboratories' current Shiller PE Ratio of 17.28 is 42% below median its 10-year median of 29.73. Over the past 10 years, this metric has ranged from a low of 13.22 to a high of 442.68. The Medical Diagnostics & Research industry median Shiller PE Ratio is 26.23. Shin Nippon Biomedical Laboratories' value of 17.28 is 34.1% below this industry median. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #26 out of 77 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Shiller PE Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #26 out of 77 companies for Shiller PE Ratio. This puts Shin Nippon Biomedical Laboratories in the upper half of its industry. The industry median Shiller PE Ratio is 26.23. Shin Nippon Biomedical Laboratories' value of 17.28 is 34.1% below this benchmark. Historically, Shin Nippon Biomedical Laboratories' own Shiller PE Ratio has ranged from 13.22 to 442.68 over the past decade. While the company's 10-year median is 29.73 vs. the industry median of 26.23, Shin Nippon Biomedical Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Medical Diagnostics & Research company?
The median Shiller PE Ratio among Medical Diagnostics & Research companies is 26.23, based on 77 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shin Nippon Biomedical Laboratories's current Shiller PE Ratio of 17.28 is 34.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Shin Nippon Biomedical Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Shiller PE Ratio is 26.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shin Nippon Biomedical Laboratories's current Shiller PE Ratio is 17.28, which is 42% below median its own 10-year median of 29.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current Shiller PE Ratio of 17.28. The stock's GF Value™ is $11.13, compared to a current price of $9.16 — trading 17.7% below its estimated fair value. The current Shiller PE Ratio is 17.28, which is 42% below median its 10-year median of 29.73 and 34.1% below the Medical Diagnostics & Research industry median of 26.23. Shin Nippon Biomedical Laboratories' overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current Shiller PE Ratio is 17.28 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of $9.16 is trading 17.7% below its estimated GF Value™ of $11.13.
Key valuation signals for SBLOF:
Shiller PE Ratio: 17.28 (42% below median its 10-year median of 29.73)
GF Value™: $11.13 vs. price of $9.16 (17.7% below fair value)
Industry Position: 34.1% below the Medical Diagnostics & Research median (#26 of 77)
No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
83GF Score
Get the complete analysis for SBLOF
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBLOF has been successfully added to your 
